Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer

<b>Background</b>: Blood-based comprehensive genomic profiling (CGP), a form of liquid biopsy, is often used for biliary tract cancer (BTC) when tissue-based CGP (tissue CGP) is unavailable, despite lower detection rates. This study explored factors linked to detecting actionable genomic alterations to optimize its use. <b>Methods</b>: We retrospectively analyzed BTC cases in Japan's C-CAT (June 2019-January 2025), restricting panel comparisons to FoundationOne<sup>®</sup> CDx (F1; n = 5019) and FoundationOne<sup>®</sup> Liquid CDx (F1L; n = 1550). Missing covariates were handled by multiple imputations (m = 20). Between-panel balance used 1:1 propensity-score matching (caliper 0.2). Outcomes were modeled with logistic regression. Targets included MSI-H, TMB-H, <i>FGFR2</i>/<i>RET</i>/<i>NTRK</i> fusions, <i>BRAF</i> V600E, <i>KRAS</i> G12C, <i>IDH1</i> mutations, and <i>ERBB2</i> amplification. An exploratory analysis stratified results by the number of prespecified enrichment factors (0-4). Liquid biopsy was performed using plasma-based comprehensive genomic profiling assays (FoundationOne<sup>®</sup> Liquid). <b>Results</b>: Missingness was low; after matching (n = 1549 per group) covariates were well balanced (all|SMD|≤0.05). Detection of any actionable alteration was lower with F1L than F1 (16.8% vs. 24.8%; OR 0.61, 95% CI 0.49-0.75; <i>p</i> < 0.001). F1L also had lower TMB-H (OR 0.62, 0.43-0.90; <i>p</i> = 0.01) and <i>ERBB2</i> amplification (OR 0.42, 0.31-0.57; <i>p</i> < 0.001), with no significant differences for MSI-H, <i>IDH1</i>, <i>KRAS</i> G12C, or <i>BRAF</i> V600E. Within F1L, non-perihilar location (OR 2.05), liver (1.90), lymph-node (1.41), and lung metastases (1.52) predicted detection of actionable genomic alterations. F1L detection increased from 5.8% (zero factors) to 32.8% (four factors), approximating tissue at three factors. <b>Conclusions</b>: The utility of liquid biopsy can be maximized by carefully selecting samples on the basis of conditions that increase the detection rate.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-09-19
DOI
https://doi.org/10.3390/cancers17183071
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer

Kento Osawa, Mitsuru Sugimoto, Hiromasa Ohira, Kentaro Sato et al.
Cancers
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer

Kento Osawa, Mitsuru Sugimoto, Hiromasa Ohira, Kentaro Sato, Rei Suzuki, Keisuke Kudo, Hiroyuki Asama, Hiroshi Shimizu, Rei Ohira
article en

Abstract

<b>Background</b>: Blood-based comprehensive genomic profiling (CGP), a form of liquid biopsy, is often used for biliary tract cancer (BTC) when tissue-based CGP (tissue CGP) is unavailable, despite lower detection rates. This study explored factors linked to detecting actionable genomic alterations to optimize its use. <b>Methods</b>: We retrospectively analyzed BTC cases in Japan's C-CAT (June 2019-January 2025), restricting panel comparisons to FoundationOne<sup>®</sup> CDx (F1; n = 5019) and FoundationOne<sup>®</sup> Liquid CDx (F1L; n = 1550). Missing covariates were handled by multiple imputations (m = 20). Between-panel balance used 1:1 propensity-score matching (caliper 0.2). Outcomes were modeled with logistic regression. Targets included MSI-H, TMB-H, <i>FGFR2</i>/<i>RET</i>/<i>NTRK</i> fusions, <i>BRAF</i> V600E, <i>KRAS</i> G12C, <i>IDH1</i> mutations, and <i>ERBB2</i> amplification. An exploratory analysis stratified results by the number of prespecified enrichment factors (0-4). Liquid biopsy was performed using plasma-based comprehensive genomic profiling assays (FoundationOne<sup>®</sup> Liquid). <b>Results</b>: Missingness was low; after matching (n = 1549 per group) covariates were well balanced (all|SMD|≤0.05). Detection of any actionable alteration was lower with F1L than F1 (16.8% vs. 24.8%; OR 0.61, 95% CI 0.49-0.75; <i>p</i> < 0.001). F1L also had lower TMB-H (OR 0.62, 0.43-0.90; <i>p</i> = 0.01) and <i>ERBB2</i> amplification (OR 0.42, 0.31-0.57; <i>p</i> < 0.001), with no significant differences for MSI-H, <i>IDH1</i>, <i>KRAS</i> G12C, or <i>BRAF</i> V600E. Within F1L, non-perihilar location (OR 2.05), liver (1.90), lymph-node (1.41), and lung metastases (1.52) predicted detection of actionable genomic alterations. F1L detection increased from 5.8% (zero factors) to 32.8% (four factors), approximating tissue at three factors. <b>Conclusions</b>: The utility of liquid biopsy can be maximized by carefully selecting samples on the basis of conditions that increase the detection rate.

CancersVol. 17(18)
Fukushima Medical University (JP)
Openalex Percentile: Top 59%
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.